It seems that high expression of PHF10 may be a candidate predictor of the efficacy of anti-PDL-1/CTLA4 therapy, and combination of PHF10 blockade and anti-PD-L1/CTLA4 mAb may be a potentially effective treatment for PAAD. Here, CTLA4 is linked to pancreatic adenocarcinoma.